elililly

#BinancePick
Lilly’s Next Growth Test: Can Retatrutide Strengthen Its Obesity Drug Leadership?

The next breakthrough in obesity treatment may not just change lives. It could reshape the future of pharmaceutical growth. 💊📈

Eli Lilly ($LLY ) is advancing retatrutide, an investigational triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors.

The latest Phase 3 results are turning heads. In the TRIUMPH-2 trial, participants with obesity and type 2 diabetes taking the 12 mg dose lost an average of 20.8% of their body weight over 80 weeks.

That is significant, but the bigger investment question is whether retatrutide can eventually expand Lilly’s market leadership beyond its existing blockbuster medicines.

The opportunity: Lilly has reported positive results across multiple Phase 3 trials and plans to submit a US regulatory application in Q1 2027.

The challenge: Retatrutide remains investigational. Regulatory review, safety, manufacturing capacity, affordability, and competition could all influence its commercial future.

Stock update: $LLY closed at $1,273.46 on October 23, 2026, down 2.54% for the session. Lilly’s Q3 earnings call is scheduled for October 29.

Prediction: Next 24 to 48 hours

My outlook is cautiously neutral to bearish after Friday’s decline. A rebound is possible if buyers return, while continued selling could extend weakness. The upcoming earnings report may influence sentiment, but no short-term direction is guaranteed.

Traders could benefit from a confirmed recovery, while momentum buyers risk losses if selling resumes.

The real test is not how much weight retatrutide can help patients lose, but whether Lilly can turn clinical success into sustainable growth.

Will retatrutide strengthen Lilly’s leadership, or is too much optimism already priced in?

For educational purposes only. Not financial advice.

#EliLilly #Retatrutide #GrowWithSAC #EarningsSeason $LLY

#BinancePick
Eli Lilly Earnings Preview: Can Mounjaro and Zepbound Sustain Their Explosive Growth?

Sometimes, a breakthrough changes not just an industry, but the scale of an entire business.

Eli Lilly ($LLY ) reports Q3 earnings on October 29, and investors will be watching whether its blockbuster medicines can keep delivering extraordinary growth.

The latest results are striking. In Q2 2026, Lilly generated $23 billion in revenue, up 48% year over year, driven primarily by Mounjaro and Zepbound.

Mounjaro revenue reached approximately $9.9 billion, while Zepbound generated $4.9 billion. Together, these medicines represented roughly 65% of Lilly's revenue during the first half of 2026.

But explosive demand is only half the story.

Lilly raised its 2026 revenue guidance to $85 billion to $87 billion. Yet lower realized drug prices, manufacturing expansion, and intensifying competition could influence how much of that growth reaches the bottom line.

Another catalyst is the pipeline. Lilly's investigational next-generation obesity medicine, retatrutide, could strengthen its longer-term growth prospects, although clinical promise does not guarantee commercial success.

My outlook: Strong prescription demand, resilient sales volumes, and confident guidance could support a bullish reaction. However, weaker pricing, disappointing forecasts, or concerns about competition could trigger volatility, even if revenue beats expectations.

The crucial question is whether Lilly can turn today's extraordinary demand into durable earnings growth.

In healthcare, a blockbuster creates opportunity. Consistent execution determines its lasting value.

Will Mounjaro and Zepbound keep powering Lilly higher, or are investor expectations becoming too demanding?

For educational purposes only. Not financial advice.

#EliLilly #WeightLossDrugs #GrowWithSAC #EarningsSeason
$LLY

#EliLilly remains in focus as investors weigh how much growth is already priced into the stock.

Shares have returned more than 55% over the past year, far outpacing the broader market. Strong second-quarter results, with revenue up 48% and solid earnings growth, continue to support the bullish case, driven largely by Mounjaro and Zepbound.


The key question now is whether prescription momentum and manufacturing capacity can keep pace with elevated expectations. Upcoming data on volume growth, international expansion, and competitive dynamics will help determine if the premium valuation holds.

$LLYB $LLY $LLY.US #LLY #Stocks #Healthcare #CoinVahini

#elilillyrises5.3%torecordhigh
🚀 Eli Lilly ($LLY ) just hit a new all-time high.👀👀

The pharmaceutical giant reached $1,290 per share, pushing its market valuation to around $1.21 trillion and joining the trillion-dollar club.

The move highlights continued investor interest in major pharma companies and the broader weight-loss drug market.

For traders, the key areas to watch:
💊 Weight-loss drug demand
📈 $LLY momentum and valuation
🧬 Biotech & healthcare sentiment
🤖 AI-healthcare developments

For crypto traders, the bigger takeaway is how strongly capital continues to chase major growth themes across markets.

Can $LLY sustain its momentum after reaching another record high?

#LLY #EliLilly #Biotech #Healthcare #Trading

🚨 Eli Lilly Hits Record High!

Eli Lilly surged around 5.3%, pushing the pharmaceutical giant to a new record as investors piled into healthcare stocks.

The move comes amid renewed excitement around the drug sector and strong momentum surrounding Lilly's weight loss and diabetes portfolio.

💊 Healthcare is back in focus. 📈 Eli Lilly is breaking out. 🔥 Investors are watching the next move.
$LLY

#EliLilly #LLY #stocks #Healthcare #BİNANCE

ELI LILLY RAISES 2026 SALES GUIDANCE

Another corporate giant just upgraded its 2026 financial forecast! Pharma power Eli Lilly bumped its full-year sales outlook to a massive $85B–$87B following a strong Q2 earnings report. 🚀

Wait a second... does something feel disconnected here? 🧐 While many retail traders are struggling through market volatility and taking heavy losses, mega-cap corporations continue to report record-breaking revenues. Who is actually winning in this market environment? 😅

What’s your strategy for the pharma space right now—buying the dip on top healthcare stocks or staying on the sidelines until market conditions settle?

⚠️ Disclaimer: Not financial advice. Always conduct your own research.

👉 New users can sign up using referral code VINHTOCDO! 🚀

#Stocks #EliLilly #Crypto #Trading #VINHTOCDO $BTC
$ETH

1st Stock Listing of the day...
$LLY
#EliLilly
Stock perpetual Contract is listing on Binance today shortly...
Listing Price Range: $1070 — $1115...

#elilillyraises2026salesoutlook
Another giant company raises its outlook for 2026! This time it’s the drug queen Eli Lilly (Eli Lilly), pumping out a massive $85–87 billion forecast after a strong performance in the second quarter. 🚀
Wait… does anyone else get a suspicious feeling here? 🧐 Traders are literally getting wiped out and living under a bridge, yet every big company prints historical revenues like it means nothing! Who actually wins in this game? 😅
What should individual traders do? Do they buy the drop in the healthcare/pharmaceutical sector, or stay safe and away from the arena?
⚠️ This is not financial advice.

Please follow.

#stocks #EliLilly #crypto #chamikametting
$BTC

#EliLillyRises5.3%ToRecordHigh Market Momentum
$LLY jumps 5.3% to a fresh record high, showing strong investor confidence and powerful momentum in the healthcare sector. Big moves like this can put major pharma stocks firmly on the market radar. 📈💊
#EliLilly
#LLY #Stocks #Healthcare #Market momentum #Investing

LLY. Eli Lilly.
Market Update: Eli Lilly & Co. ($LLY )
Eli Lilly ($LLY ) closed the last session at $1,123.86, down -2.11% (-$24.34).
The Technical Setup: The daily candlestick chart shows $LLY pulling back from its peak around $1,292.65. The price action is currently hovering right near its 99-day Moving Average (MA99 at 1,112.65), which serves as a major dynamic support level on the daily timeframe.
Key Metrics: Even with the short-term pullback, Lilly commands a massive $1.02 Trillion market capitalization, trading at a P/E ratio of 38.35 with a robust trailing EPS of $29.97.
What to Watch: After-hours/overnight data shows minor stabilization attempts up +0.14% ($1,125.46). Traders are closely monitoring the MA(99) line—a clean bounce here could signal a continuation of its long-term bullish trend, while breaking beneath it might open up a deeper retracement toward the $1,080 psychological floor.
#Follow #BinanceSquare

#EliLilly #LLY #stockmarket

$LLY is showing a heavy bearish correction on the 4-hour chart, currently trading around 1,079.26 with a daily decline of -2.77%. Following a brief surge to its 24-hour high of 1,113.96, a massive wave of selling pressure triggered a sharp, vertical drop. The price is currently resting near its local lows after breaking significantly below its previous short-term structure, indicating intense distribution. Sellers remain firmly in control, and the market will look to see if the immediate 24-hour low at 1,071.50 can hold as reliable support to prevent further breakdown.
1,071.50
1,050.00
1,022.00
#LLY #EliLilly #TradFi

📊 LLYUSDT — Pullback After Strong Move?

$LLY (Eli Lilly Perpetual) is showing a mild correction after recent strength, currently trading around $1,082 with a slight bearish pressure on the day. 📉

📌 Market Snapshot 🔹 Last Price: ~$1,082.44
🔹 24H High: $1,113.96
🔹 24H Low: $1,075.53
🔹 Volume remains steady, showing active participation

💡 What’s happening? Price is currently cooling off after a strong push — a normal retracement phase within an active trend. Buyers are still defending lower levels, but momentum has slowed.

⚠️ Key Levels to Watch • Support: $1,075 – $1,080
• Major Support: $1,060
• Resistance: $1,110 – $1,115

🎯 Trading Insight ✔️ Pullbacks like this often reset momentum
✔️ Holding support = continuation potential
✔️ Losing support = deeper correction risk

Patience is key — let the structure confirm before reacting.

$LLYUSDT #EliLilly #Trading #CryptoFutures 📊🔥

$LLYon USDT is maintaining a strong market structure with steady buying momentum. A breakout could lead to another leg higher.
📍EP: 1215 – 1225
🎯TP1: 1245
🎯TP2: 1275
🎯TP3: 1300
🛑SL: 1190
💰 Strong trend + discipline = Consistent results.
#LLYUSDT #EliLilly #StocksOnCrypto

$LLYon

🙂LLYUSDT PUMPING +4.65%? $1,228.34 BREAKING!

Eli Lilly on FIRE! Everyone on the street is watching! 👀

*Price: $1,228.34 (+4.65%)*
📈 24H High: $1,234.89
📉 24H Low: $1,172.16
💰 Vol: 5.05M USDT

Today +1.33% | 7D +2.71% | 30D +7.54%

LLY Spot: $1,227.575 (+1.56%)

Is $1,250 next? 🤔

*LONG or SHORT? Comment fast! 👇*

#LLYUSDT #EliLilly #StockTrading #Binance #LLY #Crypto #Trading #Bullish #BinanceSquare #perp

$LLYB
LLYB/USDT LONG SETUP

LLYB is trading around $1,151.78, down 3.59% today. Price has pulled back sharply from the $1,190+ area and is now testing the important $1,133–$1,145 support zone.

I would avoid chasing the drop. The better setup is to wait for support to hold and for a bullish 15m/1h confirmation.

Entry Zone
EP1: $1,145–$1,153
EP2: $1,135–$1,142

Take Profit
TP1: $1,165
TP2: $1,180
TP3: $1,198
TP4: $1,215

Stop Loss: $1,125

#LLYB #LLY #EliLilly #BinanceSquare #Write2Earn $BTC
$ASMLB

$LLYB is the tokenized bStock linked to Eli Lilly (NYSE: LLY). Binance launched LLYB/USDT Spot trading on October 7, 2026, making it a very new market with active price discovery.
💰 Price: ~$1,197.13 📈 24H Change: +2.52% 📊 24H Volume: ~$2.9M 🏦 Market Cap: ~$1.3M 📍 24H Range: $1,164.79–$1,211.32
📈 MARKET VIEW
LLYB is currently showing positive short-term momentum, with price trading close to its recent 24H high. Strong trading volume is also notable for such a new listing.
The underlying Eli Lilly stock gained 2.70% in the latest session, which provides important context for LLYB’s current movement.
🔎 KEY LEVELS TO WATCH • $1,211 area — recent 24H high • $1,165 area — recent 24H low • Volume — important for confirming whether the current momentum continues
#LLYB #EliLilly #Binance #BStocks #TokenizedAssets

My process for the $LLY price action is unglamorous. I do not predict where it goes. I check the calendar for Eli Lilly earnings and any trial or FDA dates, then decide whether I even want leveraged exposure into that window.

On the LLYUSDT perpetual, the danger is not being wrong on direction, it is being oversized when the price gaps and funding stacks up against you. So I read price action to size down, not to call tops or bottoms.

I keep leverage modest, set my stop first, and size for the volatility I can actually see. Been using Bitunix for this exposure and I factor funding into every hold. Not a guarantee, just discipline.

Plan the risk before the trade. Not advice.

$LLY #EliLilly #FuturesTrading #RiskManagement